Exhibit 99.1
INVESTORpresentation February 2021 Ofer Haviv, President & CEO
Forward Looking Statement This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, “Evogene” or “we”), that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and other securities laws. Such forward-looking statements may be identified by the use of such words as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” “intend” and “potential” or words of similar meaning. For example, Evogene is using forward-looking statements in this presentation when it discusses its near-term value drivers, including statements to the effect that it will reach commercialization, regulatory approval or enter into collaboration agreements; its milestones for each of 2021 and 2022; its belief that its diverse portfolio mitigates the risk associated with each individual opportunity within its portfolio and in its product pipeline; and its estimated cash usage for its year ending December 31, 2020. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA and other securities laws. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, the global spread of COVID-19, or the Coronavirus, the various restrictions deriving therefrom, the extent of Evogene continuing to maintain its holdings in its subsidiary companies, whether Evogene is able to comply with regulatory requirements, the degree of Evogene’s success at adapting to the continuous technological changes in its industries, and those factors and risks described in greater detail in Evogene’s Annual Report on Form 20-F and in other reports it files and furnishes with the U.S. Securities and Exchange Commission (the ”SEC”) and the Israel Securities Authority from time to time. In addition, Evogene relies, and expects to continue to rely, on third parties to conduct certain activities, such as its field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Evogene may experience significant delays in the conduct of its activities. All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene. 2
Agenda IntroductionFields of activitySummary 3 Annex I - TechnologyAnnex II - Financial Fundamentals
Our Vision 4 DECODING BIOLOGY Revolutionizing life-science product discovery & development, utilizing cutting edge computational biology technologies.
Ag-chemicalsIndustry Life-science product discovery & development challenges High cost, long time-to-market and low probability of success 5 Pharmaceutical Industry Discovery anddevelopment costsof a new cropprotection product Time to developa new cropprotection product 1995 2000 2005-8 2010-15 Number of years between the firstsynthesis and first sale of product 8.3 9.1 9.8 11.3 CDER’S* annual noveldrug approvals:2010-2019 Worldwide totalpharmaceutical R&Dspend in 2010-2024 Source: Phillips McDougall, 2016 Source: Phillips McDougall, 2016 Source: U.S. Food and Drug Administration Source: Evaluate Pharma May 2019 *Center for Drug Evaluation and Research
The opportunity Utilize comprehensive and integrated computational biology to substantially increase the probability of success, while reducing the time and cost of life-science product discovery & development. 6 HUMAN HEALTH Agriculture Other Industries
When biology meetsdisruptive technologies;introducing– platform 7 BIG DATA BIOLOGY AI Incorporating deep scientific understandings together with big data and advanced artificial intelligence technologies (AI), seeking to successfully discover & develop novel life-science based products. – Computational Predictive Biology Developed over two decades at an investment of tens of millions of dollars and validated through collaborations with industrial leaders & internal results
Tailor-made Engines for product discovery & development The CPB platform enhances product discovery and development through dedicated Engines for products based on three core components:MicrobesSmall molecules Genetic elements 8 MICROBES GENETIC ELEMENTS SMALL MOLECULES
Tailor-made Engines for product development 9 DiscoveryComputational selection of the most promising candidates to initiate the product development process. DevelopmentComputational driven solution addressingoptimization development challenges for the selected candidates, without impairing its ability to address other product attributes, supporting the way to successful commercialization. BIOLOGY BIG DATA AI MICROBES GENETIC ELEMENTS SMALL MOLECULES
A first version of our artificial intelligence-driven platform was successfully designed for hundreds of unique gRNAs for 5 different genomes, applicable in pharma, agriculture and aquaculture 10 “G O-Genome AI” Unique cross genomes database - Genome-editing capabilities
11 Business Model 1 Product development through collaborationsJoint development with leading companies for defined products utilizing Evogene’s unique solution. Later-stage development and commercialization of the product will likely be done by the partner. Potential revenue for EvogeneLicensing and research paymentsMilestone paymentsRevenue sharing GMO seed traits for yield and abiotic stress for wheat GMO seed traits for yield and abiotic stress for cornGMO seed traits for ASR resistance for soybean GMO seed traits for nematode resistance Main Business Model Until 2014: GMO seed traits for yield and abiotic stress for corn and soybeanGMO (2013) and genome editing (2019) seed traits for fusarium resistance
Product development through subsidiariesEstablish independent entities focusing on a defined commercial field with an exclusive license to use Evogene’s unique solutions for product development. The subsidiary may develop and commercialize products independently or through strategic collaborations. Potential revenue for EvogeneLicensing and research paymentsConsolidated revenuesDividends (subject to profits generated by subsidiary) 12 Business Model 2 Microbiome based therapeutics Medical cannabis Ag-solutions for castor Ag-chemicals Ag-biologicals Main Business Model from 2015:
Agenda IntroductionFields of activitySummary 13 Annex I - TechnologyAnnex II - Financial Fundamentals
OTHER INDUSTRIES AGRICULTURE HUMAN HEALTH MICROBES SMALL MOLECULES GENETIC ELEMENTS 14 Potential fields of activity
15 Current life-science based products under development OTHER INDUSTRIES AGRICULTURE HUMAN HEALTH Ag-Biologicals MicrobiomebasedTherapeutics MICROBES Ag-Chemicals Drugs based on small molecules SMALL MOLECULES Ag-solutionsfor castoroil production Seed Traits MedicalCannabis GENETIC ELEMENTS
Development & commercialization through subsidiaries and collaborations 16 OTHER INDUSTRIES AGRICULTURE HUMAN HEALTH MICROBES SMALL MOLECULES GENETIC ELEMENTS Seed Traits [division] * * non-exclusive license
Evogene group *Evogene holdings in its applicable subsidiaries Other Industries 100%* Castor Oil ProductionCastor seeds &growth protocol HumanHealth Microbiome basedTherapeuticsImmuno-oncologyGI- gastrointestinal- related disordersMDRO – multi-drug resistant organisms Medical CannabisStable high yield of specific compoundsStable high yield oftotal compounds 90%* 100%* Seed TraitsYield improvement and drought tolerancePlant diseaseInsect control Agriculture Ag ChemicalsHerbicidesInsecticidesFungicides Ag BiologicalsBio-StimulantsBio-Pesticides 98%* 72%* Internal division of Evogene 17
18 Immuno-oncology program:Combination therapy for cancer with checkpoint inhibitorsPre-clinical stageAddressable market size expected by 2026* – $243BGI related disorders:Inflammatory Bowel Disorder (IBD) – pre-clinical stageIrritable Bowel Syndrome (IBS) – discovery stageAddressable market size expected by 2026: Inflammatory Bowel Disorder - $22.4B**, Irritable Bowel Syndrome*** - $3.3BMDRO:Multi Drug Resistant Organisms (antimicrobial resistance)Clostridium Difficile Infection (CDI) – discovery stageMethicillin-resistant Staphylococcus aureus (MRSA)– discovery stageAddressable market size expected by 2026: CDI**** - $1.7B, MRSA***** – $3.9B Mission:Discovery and development of novel therapies for microbiome-related human disorders using computational biology. 2020Extend pre-clinical study in immuno-oncology program.Initiate scale-up and first GMP production of drug candidates in immuno-oncology program.2021Proof of concept, first in man study, in the immuno-oncology program.Extend pre-clinical study in IBD program. Product Pipeline: | Human Microbiome * www.globenewswire.com/news-release/2019/07/17/1884118/0/en/Cancer-Immunotherapy-Market-To-Reach-USD-242-86-Billion-By-2026-Reports-And-Data.html** www.prnewswire.com/news-releases/the-global-inflammatory-bowel-diseases-ibd-drug-market-is-estimated-at-6-7bn-in-2017-and-7-6bn-in-2023--300688523.html*** www.grandviewresearch.com/industry-analysis/irritable-bowel-syndrome-ibs-treatment-market**** www.globaldata.com/global-clostridium-difficile-infections-market-approach-1-7-billion-2026/*****www.prnewswire.com/news-releases/global-methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-to-reach-over-us-39-billion-by-2025-upsurge-in-the-consumption-of-antibiotics-across-the-globe-to-fuel-market-growth-observes-transparency-market-research-676949593.html Expected main near-term value drivers:
19 Example Results: Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone Immuno-Oncology program – BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo | Human Microbiome
20 MetaYield Products:Stable enhancement of total plant compounds:Increased compounds per plantIncreased compounds per areaTotal Cannabis market size expected by 2024 – $42.7B* Precise Products:Stable enhancement of specific active compounds for pain and inflammation Medical indication focusCompound profile focusMedical Cannabis market size expected by 2024 – $25.6B* Mission:Commercialize precise & stable medical cannabis products for better therapeutic effects using computational biology. 2020Conduct pre-clinical studies to support the development of Canonic’s medical cannabis products.Demonstrate yield improvement in cannabis lines under development.Engagement with commercial partners for cultivation and production.2021Pre-commercial activity with first cannabis variety towards commercialization in 2022.Demonstrate clinical effects of Canonic varieties based on dedicated research with a medical institution. Product Pipeline: | Medical Cannabis *Source: Arcview Market research/BDS Analytics 2020 Expected main near-term value drivers:
21 Example Results: Medical Cannabis aiming at high THC, high yield, big inflorescence and dense trichomes MetaYield products under development – increased compounds per area, addressing the T20/C4 (THC 16%-24% and CBD 0%-7%) market segment, which currently consists of 70% of the Israeli medical cannabis market | Medical Cannabis
22 Herbicides:Novel MoA (Mode-of-Action) selective/non-selective herbicidesRelevant target crops – Cereals, Rice, Corn, Soybean, Cotton, Canola, Sugar beet, Other TBDAddressable market size expected by 2022*: $34BLead stage Insecticides:Novel SoA (Site-of-Action)Addressable market size expected by 2022*: $17BHit-to-Lead stage Mission:Design of next-generation effective, sustainable and safer crop protection products by leveraging computational biology and chemistry. 2020Sign collaboration based on pre-Lead candidates from herbicide program.Reach a ‘Lead’ in herbicide program.2021Reach a POC for a herbicide tolerance gene trait, for a ‘Lead’ herbicide in development. Licensing agreement of ‘Lead’ herbicide candidate. Product Pipeline: | Ag-Chemicals *https://www.prnewswire.com/news-releases/global-3410-billion-herbicide-market-2022---research-and-markets-300458389.html Expected main near-term value drivers:
23 Example Results: Field test of APH1 against a panel of grass and broadleaf weeds – untreated control vs APH1 Leading novel MoA herbicide candidate – displaying efficacy in eradicating multiple important weed species in field tests | Ag-Chemicals (weed)
24 | Ag-Biologicals Bio-stimulants (live microbials for yield improvement):Spring wheat – seed treatment/soil application – development stage 2Corn – seed treatment – pre-development stageAddressable market size*: corn –120M ACRES, spring wheat – 25M ACRESBio-pesticides (live microbials for pest protection):Mildew, fruit rot for fruit and vegetables (initial focus on grapes) – foliar application – development stage 1Seedling disease for corn, soy – seed treatment for disease protection– pre-development stageBio-insecticides – 1st focus corn (seed treatment), soy (foliar) – application for insect protection – pre-development stageAddressable market size*: mildew, fruit rot – $550M, seedling diseases – $500M, bio-insecticides – $1.5B. Mission:Improve food quality, sustainability and agricultural productivity through the introduction of microbiome based ag-biological products using computational biology. 2020Advance phase in bio-pesticide. File for registration of a wheat bio-stimulant product and advance phase.2021Receive regulatory approval for a wheat bio-stimulant product. Advance a wheat bio-stimulant to pre-commercial activities with early-adopter farmers. Product Pipeline: *Company estimation Expected main near-term value drivers:
25 | Ag-Biologicals Example of treatment with LAV312 against Botrytis Cinerea in vines – untreated control vs treated vines Lavie Bio’s wheat field in the USA during harvest
Subsidiaries - expected main near-term value drivers(as presented at the beginning of 2020) 2020 2021 2022 Extend pre-clinical study in immuno-oncology program Initiate first GMP production of drug candidates in immuno-oncology program Extend pre-clinical study in Inflammatory Bowel Disease (IBD) program Proof of concept, first in man study, in the immuno-oncology program Engagement with commercial partners for cultivation and production Demonstrate yield improvementin cannabis lines under development Pre-commercialactivity towardscommercialization in 2022 Demonstrate clinical effects of a developed line, based on dedicated research with a medical institution Sign collaboration based on pre-Lead candidates from herbicide program Reach a ‘Lead’ in herbicide program Reach a POC for a herbicide tolerance gene trait, for a ‘Lead’ herbicide in development Licensing agreementof ‘Lead’ herbicide candidate Advance phase inbio-pesticide File for regulatory approval for a wheat bio-stimulant product & advance phase Receive regulatory approval for a wheat bio-stimulant product Advance a wheat bio-stimulant product to pre-commercial activities with early-adopter farmers 26 Collaboration Regulation Pipeline Product Launch * * Additional milestone on slide 20
Agenda IntroductionFields of activitySummary 27 Annex I - TechnologyAnnex II - Financial Fundamentals
28 Summary Our mission-Improvement of life-science product development utilizing cutting edge computational biology technologies CPB platform - a unique technology platform stemming from the incorporation of deep scientific understandings of biology together with big-data and artificial intelligence technologies Evogene’s three unique engines target to improve the development of products based on the following core components:MicroBoost AI – for products based on microbesChemPass AI – for products based on small moleculesGeneRator AI – for products based on genetic elements Four main market-oriented subsidiaries, each with a clear milestone roadmap: Biomica – human-microbiome based therapeuticsCanonic – medical cannabisAgPlenus – ag-chemicalsLavie Bio – ag-biologicals Dual based business model – utilizing Evogene’s solutions for:Product development through collaborationsProduct development through subsidiaries Significant catalysts expected in the next 12 months towards 2022 product commercialization & strategic collaborations Key shareholder since September, 2020 ARK Investment Management LLC holding ~13%* *Based on a schedule 13G filed by Ark with the SEC on October 9, 2020
THANK You!
Annex I:Technology 30
31 Efficacy Safety Selectivity Shelf-life Other ProductLaunch Candidate Selection ProductDefinition Discovery Development The challenge in creatinglife-science based products
32 Candidate Selection ProductDefinition Common practiceDiscovery – selection of product candidates mainly addressing efficacy The challenge in creatinglife-science based products Efficacy Safety Selectivity Shelf-life Other ProductLaunch
33 Candidate Selection ProductDefinition Low probability of successLong time to marketHigh development costs Development – inefficient optimization & difficulty in addressing a single challenge without impairing others The challenge in creatinglife-science based products Efficacy Safety Selectivity Shelf-life Other ProductLaunch Common practiceDiscovery – selection of product candidates mainly addressing efficacy
Evogene’s AI-based solution:Discovery 34 Candidate Selection ProductDefinition A multi-attribute computational selection of product candidates, addressing relevant challenges using dedicated training data sets and AI. Efficacy Safety Selectivity Shelf-life Other ProductLaunch
Evogene’s AI-based solution:Development 35 Candidate Selection ProductDefinition A multi-attribute computational analysis, addressing a specific development challenge of the selected candidate, without impairing its ability to address other product attributes. Efficacy Safety Selectivity Shelf-life Other ProductLaunch
36 Evogene’s AI engines provide tailor-made solutions Development Computational driven solution for guiding and assessing the optimization process of the selected core component, without impairing other key product attributes. DiscoveryComputational prediction of candidates, to serve as the product’s core-component, addressing multiple key product attributes.
Annex II:Financial Fundamentals 37
Key Financials:Balance Sheet Key Points:Consolidated cash position: ~$43.5 million as of 30.09.2020No bank debtEstimated net cash usage for 2020 (without Lavie Bio):$13-$15 millionListed on TASE (2007) and NASDAQ (2013) 38 Thousands of US $ 30.09.2020 31.12.2019 Current Assets 45,392 49,027 Long-Term Assets 20,593 22,337 Total Assets 65,985 71,364 Current Liabilities 4,639 5,746 Long-Term Liabilities 5,276 5,401 Equity attributable to equity holders of the Company 44,930 50,144 Non-controlling interest 11,140 10,073 Total Liabilities & Shareholders Equity 65,985 71,364 38